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Current inactivated whole or subunit influenza vaccines induce antibodies to the
hemagglutinin that are specific forthe virus in the vaccine orfor closely related virus
strains; however, frequent antigenic variation ofsitesonthe HA1 subunitofinfluenza
virus hemagglutinin (HA)' (l, 2) has been postulated to explain low levels ofvac-
cine efficacy (3, 4). A search for more crossreactive epitopes that may serve as pro-
tective immunogens appears reasonable in an effort to providebetter vaccineefficacy
against virus strains that vary antigenically in their antibody binding sites.
Several laboratories have reported that influenza virus-specific CTL recognize
antigenic sites that are more conserved than the siteson the HAthatbind antibodies
(5-8). Furthermore, it has been demonstrated that adoptive transfer ofinfluenza-
specific CTLcanlimit virusreplication in the respiratory tract ofmice infected with
influenzavirus (9-11). Recently, influenzanucleoprotein (NP)-specificcytotoxicT cell
clones have been shown to reduce the replication of virus and protect mice from
lethal influenza infection (12), and Townsend et al. (13) defined a peptide region
ofNP that was recognized by this protective CTL clone. NP-enriched preparations
have been reported to protect mice against challenge with virus that contained the
same NP (14).
We have demonstrated that c13 protein, a hybrid protein of the first 81 amino
acids (aa) ofthe viral NSI nonstructural protein and the HA2 subunit ofA/PR/8
(H1N1) HA, induced H1 subtype-specific CTL after secondary stimulation invitro
(15, 16). In addition, we have observed that passive transfer ofCTL clones estab-
lished by stimulation with a derivative of c13 protein, having 65 as deleted from
the NH2-terminal end ofthe HA2 subunit, significantly reduced virus titers in lungs
ofmice infected with virus strains of Hl or H2 subtypes (17). We recently demon-
strated that the epitope recognized by the protective CTL clone maps to an 11-aa
residue on the transmembrane region of the HA2 subunit (unpublished work). It
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is important to determine whether peptides or fusion proteins, which contain sites
that induce CTL and are better conserved than the antibody binding sites on the
HA1 subunit, might actively induce crossreactive protection against influenza A viruses
that undergo frequent antigenic mutations. We now report the results of virus chal-
lenge experiments performed in mice immunized with the HA2 subunit containing
fusion protein. The results demonstrate that active immunization with a fusion pro-
tein that contains a crossreactive CTL site confers significant protection against in-
fection with viruses that have undergone marked antigenic drift and antigenic shift
in the antibody binding sites on the HA.
Materials and Methods
Mice.
￿
Male BALB/c mice were purchased from Charles River Breeding Laboratories,
Inc. (Stone Ridge, NY) and used at the age of 4-5 wk.
Virus.
￿
Influenza A viruses, A/PR/8 (A/Puerto Rico/8/34 [HIN1]), A/BZ (A/Brazil/11/78
[HIN1]), A/TW (A/Taiwan/1/86 [HIN1]), A/JAP(A/Japan/305/57 [H2N2]), A/PC (A/Port
Chalmers/1/73 [H3N2]), and A/X31 (H3N2), a recombinant strain obtained by reassort-
ment of genes between A/PR/8 and A/Hong Kong/1/68 (H3N2), were propagated in 10-d-
old embryonated chicken eggs. Infected alloantoic fluids were harvested 2 d after infection,
aliquoted, and stored at -80°C until use.
Production of Influenza Virus-speck Protein in Escherichia coli.
￿
c13 and D proteins were pro-
duced in E. coli as described previously (15, 16). Briefly, plasmids containing DNA fragments
complementary to the viral RNA of A/PR/8 virus were manipulated to achieve expression
of c13 and D protein, which are hybrids of the first 81 as of NS1 fused to the entire HA2
subunit (aa 222), or to the 157 as from the COOH-terminal end of HA2, respectively. D
protein has a linker sequence (glutamine-isoleucine-proline) inserted between as 81 of NSl
and aa65 of HA2. After lysis of the bacteria, two 0.1% deoxycholate extractions and one 1%
Triton X-100 extraction were performed to remove contaminating E. coli proteins, and the
c13 and D protein were solubilized with 4 M urea at 4°C for 30 min. The urea was then
removed by dialysis at 4°C. The prepared proteins were stored in 50 mM Tris-HCI, pH 8.0,
1 mM ED A.
Immunization of Mice.
￿
Mice were immunized with 200 Fig or 300 hg of c13 protein in-
traperitoneally without adjuvants or with 100 plaque forming units (PFU) of the A/PR/8
virus intranasally under ether anesthesia.
CTL Assay.
￿
1 wk after the last immunization, spleen cells of mice were taken for in vitro
stimulation with virus. CTL assays were carried out as described previously (15, 16). Briefly,
3 x 10' spleen cells from immunized or control mice were cultured with 3 x 106 syngeneic
normal spleen cells infected with A/PR/8 or A/PC virus at a multiplicity of 10 PFU per cell.
After 5 d of culture these cells were used as effector cells. For target cells, 2 x 106 P815
(mastocytoma: H-2e) cells were incubated with A/PR/8, A/JAP, or A/PC virus at a mul-
tiplicity of 10 PFU per cell in the presence of 250 pCi "Cr, and 104 5'Cr-labeled target cells
were incubated with effector cells at the indicated ratios in a 96-well round-bottomed microplate
for 4 h. The supernatant fluids were harvested and 5'Cr was measured in a gamma counter.
Percent specific lysis was determined as follows : percent specific lysis = 100 x (experimental
release - minimum release)/(maximum release - minimum release) where spontaneous
release was determined by incubating P815 cells in medium, and maximum release by in-
cubating P815 cells in 10% Renex 30 solution (Ruger Chemical Co., Irvington, NJ). E/T
ratios varied from 3 :1 to 200:1 as listed, and quadruplicate samples were tested at each E/T ratio.
Virus Challenge.
￿
1 wk after the last immunization, mice were challenged intranasally under
ether anesthesia with 5 x 104 PFU of A/PR/8, A/TW, A/JAP or A/PC viruses. 4 d later
lungs were harvested for measurement of pulmonary virus titers.
Titration ofPulmonary Virus.
￿
Harvested lungs were manually homogenized in 1 .5 ml of
PBS followed by centrifugation (2,000 g for 15 min at 4°C). Supernatants were frozen until
they were titrated for virus. Madin Darby canine kidney (MDCK) cells were maintained
in MEM containing 100 U/ml penicillin, 100 4g/ml streptomycin, and 292 J4g/ml L-glutamineKUWANO ET AL.
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supplemented with 10% heat-inactivated FCS, and were seeded (25 x 104 cells in 1 ml
MEM) in 24-well tissue culture plates. Lung supernatants were thawed and serially diluted
in PBS containing 0.1 % BSA. After aspiration ofmedium from the wells, 100 p,l ofthe diluted
virus solution was added to each well and incubated at 37°C for 1 h with occasional agitation.
Each well then received 1 ml of agar medium containing MEM, 0.170 n-glucose, 0.017o DEAE-
Dextran, 1% vitamins, 10 Rg/ml trypsin, and 1% agar. After 2 d incubation in 5% COZ at
37°C, 1 ml of 10% neutral red in PBS was overlaid on agar in each well. Plaques were counted
after 10 h incubation. The results were expressed as the mean logo PFU/ml of duplicate
samples.
CTL Clones.
￿
CTL clones were established as described previously (17, 18). Briefly, A/PR/8
immune spleen cells were cultured with normal syngeneic spleen cells infected with A/PR/8
virus or exposed to D protein. CTL responder cells were stimulated with A/PR/8 or D pro-
tein-pulsed normal syngeneic -y-irradiated spleen cells in the presence of 10% rat IL-2 for
5-8 wk. A limiting dilution was carried out to develop CTL clones. Viable responder cells
(0.5, 1, 2, 4, 8, and 16 cells/well) were cultured in wells of 96-well flat-bottomed microtiter
plates (Costar, Cambridge, MA) with 106 syngeneic, A/PR/8, or D protein-pulsed, -y-ir-
radiated BALB/c spleen cell in 0.2 ml of medium. Stimulator cells were added every 7 d.
B-7 or A-11 clones described in this paper grew from a well in which four or two responder
cells had been seeded, respectively, as described (17) .
Cold Target Inhibition Test.
￿
P815 cells infected with various viruses or coated with D protein
(50 l~g/ml) for 90 min at 37'C were added to the CTL assay, in which B-7 CTL clone was
incubated with "Cr labeled P815 target cells infected with A/PR/8, at the indicated ratios.
Titration ofNeutralizing Antibody.
￿
Neutralizing antibody against A/PR/8 virus was deter-
mined by a plaque assay in MDCK cells. Serially diluted pooled sera were preincubated with
20 PFU of virus at 37°C for 1 h and were titrated for virus as described above. The 50%
plaque-neutralizing antibody titers were calculated. Pooled sera of mice that had been in-
fected intranasally 6 wk earlier with 100 PFU of A/PR/8 virus were included as a positive control.
Results
VirusSpecificity ofc13Immune Spleen CellsStimulatedby Viruses.
￿
We immunized BALB/c
mice with c13 protein to determine whether immunization would induce protection
against influenza infection via induction of CTL. Preliminary experiments had in-
dicated that CFA did not significantly enhance the level of c13 protein induced CTL
activity. Table I shows that the spleen cells of c13 immunized mice that were stimu-
lated by A/PR/8 virus-infected normal syngeneic spleen cells in vitro were able to
lyse A/PR/8 infected target cells, although to a lower degree than A/PR/8-immune
effector cells stimulated by A/PR/8 infected normal spleen cells, and they did not
lyse A/PC (H3N2) virus-infected target cells or uninfected target cells. We found
no detectable CTL activity in c13 protein-immune spleen cells after stimulation by
A/PC (H3N2) virus. Spleen cells of nonimmune mice also failed to show CTL ac-
tivity on any target cells after stimulation with virus in vitro.
Pulmonary Virus Titers ofc13Immune Mice Infected with A/PR/8 (HINT) orA/PC (H3N2)
Viruses. We next examined the pulmonary virus titers of c13 protein-immunized
mice and nonimmune mice after challenge with A/PR/8 (HlN1) or A/PC (H3N2)
viruses. The c13-immunized mice had significantly lower pulmonary virus titers of
A/PR/8 virus compared with the lung virus titers of nonimmunized mice. There
was no difference in the pulmonary virus titers between c13-immunized mice and
nonimmune mice after challenge with the heterotypic virus, A/PC (H3N2) (Table II).
Survival ofc13-immune Mice after A/PR/8 Challenge.
￿
After a lethal challenge with
5 x 104 PFU ofA/PR/8 virus, seven of eight c13-immunized mice survived beyond
day 60 (last day of observation), but all of nonimmune mice were dead by day 71364
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TABLE I
Virus Specificity of c13-immune Spleen Cells Stimulated by A/PR/8
(HINT) or AIPC (H3N2) Viruses
* Each group consists of six mice.
I p < 0.005, determined by Student's t test.
Virus-infected (A/PR/8, A/PC) and uninfected P815 target cells were tested
at the indicated E/T cell ratios.
* 4-wk-old mice were given 200 Ag of cl3 protein intraperitoneally and repeat
doses 3, 4, and 5 wk later.
(Fig. 1). This protection induced by c13 protein reflects the specificity of lysis by
the virus stimulated c13 immune spleen cellsofA/PR/8-infected target cells in vitro,
and the specific limitation of A/PR/8 virus replication in the lungs of mice that had
been immunized by c13 protein.
HA Epitope Specificfor CTL Is Conserved.
￿
We wanted to determine if immuniza-
tion would afford protection against variant Hl subtype virus strains across the H1
subtype. First, we performed a CTL assay and a cold target inhibition assay using
influenza Hl subtype viruses A/PR/8, A/BZ, and A/TW, which were isolated in
1934, 1978, and 1986, respectively. We used as effector cells a CTL clone designated
B-7, which had been stimulated with D protein, a derivative of c13 protein (17). As
shown in Table III, the B-7 clone lysed target cells infected with each of the Hl sub-
type virus strains, but failed to lyse A/PC (113M)-infected target cells. As a positive
control, the A-11 CTL clone stimulated with live A/PR/8 virus killed target cells
TABLE II
Pulmonary Virus Titers of c13-immunized Mice
Stimulation Percent specific lysis of target cells
In vivo In vitro A/PR/8 (HlN1) A/PC (H3N2) Uninfected
1°-4° 5° 200 60 20 200 60 20 200 60 20
c13 A/PR/8 30 13 5 1 0 2 - 3 - 3 - 3
A/PC - 1 3 3 0 - 1 0 1 0 3
None 2 0 -1 0 -1 -2 -4 -3 -3
None A/PR/8 0 - 2 - 1 - 1 - 1 - 1 - 4 - 4 - 3
A/PC -1 -1 0 1 1 0 -1 -3 -1
None 0 0 2 - 1 0 2 - 4 - 4 - 2
In vivo In vitro A/PR/8 (HINT) A/PC (H3N2) Uninfected
1° 2° 25 8 3 25 8 3 25 8 3
A/PR/8 A/PR/8 65 32 11 59 31 20 4 6 0
A/PC 32 10 8 34 16 8 - 3 - 4 - 1
None -1 -2 -3 0 -1 -1 -3 -4 -3
Recipients
Immunization Virus challenge Virus titer
c13 A/PR/8 (HINI) 3 .8 t 0.91
None A/PR/8 5.4 t 0.21
c13 A/PC (H3N2) 5 .4 ± 0.2
None A/PC 5 .0 t 0.3too
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FIGURE 1 .
￿
Survival ofmice after lethal A/PR
virus infection. Symbols are as follows: (O)
c13 protein immunized mice; ( ") nonim-
munized mice. 1 wk after the fourth immu-
nization (Table 1), mice were intranasally chal-
lenged with A/PR/8 virus at a dose of 5 x 104
PFU under ether anesthesia and were ob-
served for survival. The difference in survival
between the two groups was significant (p <
0.001), as determined by Fisher's exact prob-
ability test.
infected with virus strains of the H1 and H3 subtypes. Cold target inhibition experi-
ments revealed that lysis of A/PR/8-infected cells was inhibited by both A/PR/8 and
A/BZ virus-infected cold targets and by D protein-coated cold target cells. Neither
A/X31 (H3N2) infected cold target cells nor uninfected cold target cells competed
with the "Cr-labeled target cells (Fig. 2). These results indicate that an epitope on
the HA2 subunit of influenza H1 subtype virus strains is highly conserved, and is
recognized by the D protein-stimulated CTL clone.
Protection ofMice Infected with AITWby c13 Immunization.
￿
We examined whether
c13 protein-immune mice would also be protected against a recently isolated Hl
subtype virus strain, A/Taiwan/1/86 (HIND. The results shown in Table IV demon-
strate that the c13 protein-immunized mice had significantly lower lung virus titers
of A/Taiwan/1/86 after challenge than did nonimmune mice; however, neither the
c13 protein-immunized nor control nonimmune mice had serum neutralizing anti-
bodies against A/PR/8 virus, which was the source of the genes for NSl and the
HA2 subunit used to make this fusion protein c13. This was expected because the
HA2 subunit does not contain sites that induce neutralizing antibodies. In contrast,
A/PR/8 virus-primed mice, sampled as positive controls, showed high levels ofneu-
TABLE III
Recognition of Target Cells Infected with HI Subtype Virus Strains
by an HA2 Subunit-specie CTL Clone
' Clone B-7, which expresses 97% of Thy-1 .2, 95 % ofLyt-2, and 0 % of L3T4
surface antigens, was stimulated with D protein.
1 Clone A-11, which expresses 99% ofThy-1 .2, 94% of Lyt-2, and 2% ofL3T4
surface antigens, was stimulated with A/PR/8 virus.
Percent specific lysis
CTL clone E/T ratio
A/PR/8
(HIND
A/BZ
(HlNl)
A/TW
(HIND
A/PC
(H3N2) Uninfected
B-7* 1 .0 77 83 58 0 0
0.5 61 68 47 0 0
A-111 1 .0 66 74 43 48 0
0.5 45 49 31 29 01366
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Cold-target inhibition test. Cytotoxicity of clone B-7
on A/PR/8-infected P815 cells was measured in the presence of
various unlabeled target cells at the indicated ratios.
tralizing antibody titers. These results suggest that immunization with c13 protein
induced protection against virus strains of the H1 subtype isolated in 1934 and 1986
by the induction ofCTL responses, and not by the induction of neutralizing antibody.
Induction of Crossreactive-specific CTL by c13-immune Spleen Cells.
￿
We then examined
whether c13-immune mice would be protected against challenge with a virus ofthe
H2 subtype. Table V shows that c13-immune spleen cells stimulated by A/PR/8 virus
lyse the A/PR/8 (H1) virusor A/JAP (H2) virus-infected target cells, but not A/PC
(H3) virus-infected target cells. The level of A/JAP-infected target cells lysis by
c13-immune spleen cells stimulated with A/PR/8 virus was about half of that of
A/PR/8-infected target cells lysed by the effector cells and was significant. On the
contrary, A/PC (H3) virus-stimulated c13-immune spleen cells did not lyse any of
virus-infected target cells. As a positive control, A/PR/8 virus-immune spleen cells
stimulated by A/PR/8 virusor A/PC virus showed significant lysisof all ofthe virus-
infected target cells. These results suggest that c13-immune spleen cells contain a
population of H1-H2 crossreactive CTL precursors, since c13-immune spleen cells
stimulated by A/PR/8 virus showed crossreactive lysis of target cells infected with
A/PR/8 (Hl) or A/JAP (H2) viruses. In addition, we have observed that the lysis
of A/PR/8 virus infected target cells by clone B-7 specific for HA was inhibited by
TABLE IV
Pulmonary Virus Titer of c13-immunized Mice
* p < 0.005, as determined by Student's I test. An additional 200-Wg dose of c13
protein was given to mice (five mice each group) 3 wk after the fourth immu-
nization (Table 1). Before challenge, serum was obtained from c13 pro-
tein-immunized mice for titration of neutralizing antibody to A/PR/8 .
Recipients
Neutralizing
Immunization Virus challenge Virus titer antibody titer
c13 A/TW (HIND 2.5 ± 0.9` <4
None A/"1'W (HIN1) 4.1 ± 0 .3" <4
A/PR/8 ND ND 256KUWANO ET AL.
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TABLE V
Crossreactive Specificity of c13-immune Spleen Cells Stimulated by A/PR/8 Virus
Virus-infected (A/PR/8, A/JAP, A/PC) or uninfected P815 target cells were tested at the indicated E/T ratios.
' 4-wk-old mice were given 300 Wg of c13 protein intraperitoneally and repeat doses 3, 4, 5, 6, and 7 wk later.
A/JAP virus-infected target cells (data not shown), which supports the existence
of H1-H2 crossreactive CTL population in the c13-immunized mice.
Reduction of Pulmonary Virus Titer of c13-immune Mice Infected with A/,JAP (H2N2)
Virus. We assessed the ability ofc13 immunized mice against challenge with virus
of the H2 subtype. We injected mice that had been immunized with six doses of
c13 protein as shown in Table V, with A/JAP (H2N2) virus, A/PR/8 (H1N1), or
A/PC (H3N2) viruses. The sera from these c13-immunized mice were tested before
the mice were challenged with virus. The sera did not contain any detectable plaque
neutralizing antibodies (<1 :4) against A/PR/8, A/JAP, or A/PC viruses, as expected
from the results of our earlier experiment shown in Table IV. Table VI shows that
c13 immune mice had significantly lower lung virus titers than control mice after
challenge with the A/PR/8 (Hl) or A/JAP (H2) viruses, but not with A/PC (H3)
virus. These results appear to reflect the in vitro CTL activity in Table V, where
the induction of H1-H2 crossreactive CTL was shown.
TABLE VI
Reduction of Pulmonary A/JAP Virus Titer of c13-immunized Mice
* Each group consists of four mice.
1 Influenza viruses were challenged one week after the sixth immunization as
shown on Table V.
4 p < 0.02, determined by Student's t test.
~~ p < 0.02, determined by Student's t test.
Stimulation* Percent specific lysis of target cells
In vivo In vitro A/PR/8 (HIN1) A/JAP (H2N2) A/PC (H3N2) Uninfected
1°-60 7° 200 60 20 200 60 20 200 60 20 200 60 20
c13 A/PR/8 73 50 24 38 18 10 10 4 0 11 4 1
A/PC 1 0 0 - 1 0 2 0 0 0 0 0 0
None 6 1 1 5 1 4 3 1 1 3 0 1
In vivo In vitro A/PR/8 (HIN1) A/JAP (H2N2) A/PC (H3N2) Uninfected
10 20 30 10 3 30 10 3 30 10 3 30 10 3
A/PR/8 A/PR/8 54 35 20 50 27 12 51 27 13 3 1 1
A/PC 39 19 7 37 21 9 48 20 8 1 0 0
None 2 1 0 3 1 2 4 2 0 2 1 1
Immunization
Recipients*
Virus challengel Virus titer
c13 A/PR/8 (HIN1) 4.7 ± 0.44
None A/PR/8 5.8 + 0.84
c13 A/JAP (H2N2) 4.0 ± 0.311
None A/JAP 4.8 ± 0.411
c13 A/PC (H3N2) 4.4 t 0.3
None A/PC 4.2 t 0.21368
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Discussion
The composition of influenza vaccines is regularly revised due to the frequent
antigenic variation of the antibody binding sites on the HAI subunit of the HA.
Despite these efforts, vaccine efficacy is less than desired. We hypothesized that the
induction ofCTL responses to conserved epitopes would protect mice against infec-
tion with influenza virus strains with altered antibody binding siteson the HA. Mice
immunized without adjuvants with a hybrid protein that contains the HA2 subunit
of A/PR/8/34 (H1N1) HA developed specific CTL responses, and were protected
against challenge with A/PR/8/34 virus and the recently isolated A/Taiwan/1/86 virus
strain, without the induction of neutralizing antibodies. In addition to this cross-
reactive protection within the Hl subtype, immunized mice were also protected against
challenge with virus of the H2 subtype, reflecting the in vitro specificity of the CTL
epitope on the HA2 subunit. These results demonstrate that immunization with
a fusion protein that contains the HA2 subunit of influenza A (A/PR/8) virus in-
duced protection against influenza A Hl subtype virus strains isolated over 50 yr
apart that have great diversity in hemagglutinating-antibody specificities, and also
provides crossreactive protection against challenge with an H2 subtype virus. Al-
though we have not tested it directly, c13 protein might induce protection against
all of Hl and H2 subtype virus strains. This seems reasonable because we have pre-
viously demonstrated that CTL clones stimulated with a derivative of c13 protein
exhibit crossreactive lysis oftarget cellsinfected with Hl and H2 subtype virus strains,
and that passive transfer of such a clone restricts virus replication in mice infected
with virus strains of the Hl or H2 subtypes (17). Further, we now report reduced
lung virus titers after challenge with H1 and H2 subtype viruses . We assayed the
sera of c13 immunized mice for neutralizing antibodies to rule out the possibility
that such antibodies might contribute to this protection and found none. This was
expected because the antibody binding sites for virusneutralization are on the HAI
subunit of HA (19, 20). Thus, such a fusion protein that contains a conserved CTL
epitope offers promise for the potential development of influenza vaccines by in-
ducing protective crossreactive CTL responses. We have recently observed that the
crossreactive CTL epitope on the HA2 maps to an 11-aa residual in the transmem-
brane region of the HA2. We have been able to stimulate the proliferation of the
protective B-7 CTL clone, induced by the fusion protein, using this 11-aa peptide,
and this peptide renders target cells susceptible to lysis by this CTL clone. We have
also succeeded in inducing a CTL line from A/PR/8 immune spleen cells using this
synthetic peptide (data not presented). We will attempt to prime mice in vivo with
this peptide in future experiments .
Crossreactive memory CTL responses to influenza viruses have been detected in
humans (21-23), and these may contribute to recovery from infection (24) with virus
strains that are antigenically different at HAI antibody-combining sites, thus bypassing
neutralizing antibodies. It is not clear why these crossreactive memory CTL responses,
which result from natural infection, are not more protective to humans after viral
challenge with variant strains. Studies in mice (25) and humans (26) suggest that
the ability of current influenza vaccines to induce CTL responses is limited, and
the reasons for this are not known. Perhaps immunization with crossreactive CTL
epitopes can be better accomplished by use of small fusion proteins or peptides. ItKUWANO ET AL.
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is, however, reasonable to expect that such small peptides or fusion proteins may
demonstrate HLA haplotype preferences. Gotch et al. (27) have noted haplotype
preference with peptides of NP and matrix protein, and we have reported haplo-
type preference in mice (16), and have also noted it with human PBL lymphocytes
(data not presented) with this fusion protein. These questions must be addressed
in future studies, but the design ofmore crossreactive influenza vaccines based on
conserved sites that areactive in CTL induction appears worthwhile as an approach
for future vaccine development.
Despite their promise, synthetic peptides have not been successfully developed
as vaccines, because oftheir failure in general to induce protective immunity (28).
The limited protection that has been noted usually required carriers and adjuvants
(29), but anexception wasreported withahybrid synthetic peptide(141-158 + 200-213
aa) of the virus coat protein (VPI) offoot and mouth disease virus, which induced
neutralizing antibody (30). The ability of this influenza-derived fusion protein to
actively immunize against influenza A virus strains, which vary markedly in their
antibody binding sites on the HAl, may be due to the presence ofas yet undefined
T helper determinants on the fusion protein that assist the CTL responses to the
conserved cytotoxic T cell epitope on the HA2 subunit. Perhaps the failure ofpep-
tides to protect in other systems (28) may be due to the absence of such T helper
and CTL sites. The results reported here suggest a model for more crossreactive
vaccines against antigenically variant viruses, such as influenza A, or HIV1.
Summary
We have examined whether active immunization with c13 protein, a hybrid protein
ofthe first81 aminoacids oftheviral NSI nonstructural protein and theHA2 subunit
ofA/PR/8 (HIN1) hemagglutinin, could protect BALB/c mice from challenge with
A/PR/8 H1 subtype virus. Mice immunized with the c13 protein had a significant
reduction ofpulmonary virus titers with A/PR/8 (Hl) virus, but failed to limit the
replication ofA/PC (H3) virus, which reflects the in vitro CTL activity ofc13 im-
mune spleen cells. We observed that the epitope recognized by HA2 specific CTL,
which areinduced by a derivative ofc13 protein, ishighly conserved among H1 and
H2 subtype virus strains. This led us to test whether active immunization with c13
protein wouldalsolimitpulmonary virus replicationin mice infectedwiththe A/TW
virus, a virus of the H1 subtype, which was isolated in 1986, and with a virus of
the H2 subtype, A/Japan/305/57. Immunized mice hadsignificantly lower lungvirus
titers than did control mice, and did not possess any neutralizing antibodies to the
challenger viruses. These results indicate that active immunization with a fusion
protein containing the cross-reactive CTL epitope protects mice from influenza in-
fectionby inducingCTL againstinfluenzaA Hl and H2 subtype virus strains, which
markedly vary in their antibody binding sites on the HAl. The ability to induce
active cross-reactive immunization with a fusion protein which contains a highly
conserved CTL epitope offers amodel forvaccine approaches against viruses which
undergo significant variations in their antibody binding sites.
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